BACK

BCMA/CD19 dual target

CompoundAZD0120

Area under investigation

Multiple myeloma

Scientific PillarCell Therapy

Target Overview

B-cell maturation antigen (BCMA) is universally expressed on malignant plasma cells.1 CD19 is expressed on both multiple myeloma cells and their progenitors2 and is a recognized target for other hematologic malignancies and autoimmune diseases.

Compound Overview

AZD0120 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy, dual-targeting B-cell maturation antigen (BCMA) and CD19, and manufactured on the novel FasT CAR-T cell platform.3 AZD0120 has been acquired from Gracell Biotechnologies.

Mechanism of Action

  • Mechanism of Action

AZD0120 was formerly named GC012F, and next-generation manufacturing refers to the
FasTCAR platform.

References

1. Tai YT, Anderson KC.  Immunotherapy. 2015;7(11):1187-1199. 2. Boucher K, Parquet N, Widen R, et al. Clin Cancer Res. 2012;18(22):6155-6168. 3. Du J, Fu W, Jiang H, et al. Poster presented at ASCO 2023.

Clinical trial information


Select trial for more information

Arrange By

Abbreviations

View full glossary

  • BCMA

    B-cell maturation antigen

  • CAR-T

    chimeric antigen receptor T cell (therapy)

  • CD19

    cluster of differentiation 19

  • MM

    multiple myeloma

Some compounds herein refer to selected AstraZeneca pipeline products still under development. AstraZeneca pipeline products are investigational products and, as such, are not approved by the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory agency for the uses under investigation. Information regarding these investigational products should, under no circumstances, be regarded as a recommendation for their use or of their safety or efficacy.

This site is intended for US Healthcare Professionals.

Veeva ID: Z4-80919 US-109129 DE-92568 Last Updated April 20263/26
©2026 AstraZeneca. All rights reserved.